Axsome Therapeutics' SWOT analysis: stock poised for growth amid CNS breakthroughs
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company has been gaining significant ...
TD Cowen lifts Axsome stock target to $155, maintains Buy rating
TD Cowen, a well-established research firm, increased its price target on Axsome Therapeutics (NASDAQ:AXSM) shares, raising the figure to $155 from the previous target of $125. The firm reaffirmed its ...
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
RBC Capital analyst Leonid Timashev maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of ...
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Nurix Therapeutics (NRIX) and Merit Medical Systems (MMSI)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Axsome Therapeutics (AXSM – Research ...
William Blair Reiterates “Outperform” Rating for Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “outperform” rating reiterated by investment analysts at ...
Axsome Shares Rise 19% in a Month: What's Driving the Rally?
AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while ...
Axsome Therapeutics (NASDAQ:AXSM) Earns Buy Rating from HC Wainwright
Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report issued ...